Compare Moderna, Inc. (MRNA) vs Sprott Uranium Miners ETF (URNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Sprott Uranium Miners ETF — how do they compare? Moderna, Inc. trades at $135.92 (market cap $56.02B), while Sprott Uranium Miners ETF trades at $56.37. The key difference: Moderna, Inc. is trading nearer its 52-week high, Sprott Uranium Miners ETF nearer its low. Which is the better fit depends on your goals.
| MRNA | URNM | |
|---|---|---|
Market Cap | $56.02B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $174.38 | $83.99 |
52-Week Low | $22.36 | $47.13 |
Enterprise Value | $52.17B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $140.33, down 3.59% on the day, but maintains a bullish technical signal with support at $138 and resistance at $145. Recent positive phase 3 cancer vaccine trial results have driven significant stock appreciation, though financials show declining revenue and negative net income margins. The company has beaten EPS estimates for the last three quarters, with Q3 2026 results pending.
The outlook is mixed; promising clinical developments in oncology offer long-term growth potential, but high valuation multiples and persistent losses pose risks. Analyst consensus is cautious with a $90.08 price target below the current price, reflecting concerns over profitability and competitive pressures in the mRNA therapeutics space.
URNM, the Sprott Uranium Miners ETF, trades at $57.38, up 0.54% on the day, with a neutral technical signal. Key support lies at $57 and resistance at $58. The ETF offers concentrated exposure to uranium miners, benefiting from long-term supply deficits and rising demand driven by nuclear energy adoption for AI power needs. Recent news highlights strong fundamentals, including government funding and tech company reactor deals.
Outlook remains positive due to structural uranium supply shortages and increasing nuclear energy demand, though volatility risks persist from price swings and geopolitical factors. Analyst sentiment is mixed, with some advocating pure-miner exposure for higher upside, while others caution on valuation divergences from spot uranium prices.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Sprott Uranium Miners ETF
URNM is a pure-play ETF that invests in the global uranium industry. It provides exposure to companies involved in the mining, exploration, and production of uranium, as well as physical uranium holdings, with top assets like Cameco, Uranium Energy Corp, and the Sprott Physical Uranium Trust.
Read more on URNM →
